[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2009012761A - Neramexano para el tratamiento de nistagmo. - Google Patents

Neramexano para el tratamiento de nistagmo.

Info

Publication number
MX2009012761A
MX2009012761A MX2009012761A MX2009012761A MX2009012761A MX 2009012761 A MX2009012761 A MX 2009012761A MX 2009012761 A MX2009012761 A MX 2009012761A MX 2009012761 A MX2009012761 A MX 2009012761A MX 2009012761 A MX2009012761 A MX 2009012761A
Authority
MX
Mexico
Prior art keywords
neramexane
nystagmus
treatment
individual
administering
Prior art date
Application number
MX2009012761A
Other languages
English (en)
Inventor
Angelika Hanschmann
Albrecht Stoeffler
Michael Althaus
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2009012761A publication Critical patent/MX2009012761A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con el tratamiento de un individuo diagnosticado con nistagmo que comprende administrar al individuo una cantidad efectiva de un derivado de 1-aminoalquilciclohexano, por ejemplo neramexano, o una sal farmacéuticamente aceptable del mismo, tal como mesilato de neramexano.
MX2009012761A 2007-06-08 2008-06-06 Neramexano para el tratamiento de nistagmo. MX2009012761A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93380807P 2007-06-08 2007-06-08
EP07252336 2007-06-08
EP08006925 2008-04-07
PCT/EP2008/004531 WO2008148564A1 (en) 2007-06-08 2008-06-06 Neramexane for the treatment of nystagmus

Publications (1)

Publication Number Publication Date
MX2009012761A true MX2009012761A (es) 2009-12-16

Family

ID=39719088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012761A MX2009012761A (es) 2007-06-08 2008-06-06 Neramexano para el tratamiento de nistagmo.

Country Status (12)

Country Link
US (1) US20100234358A1 (es)
EP (1) EP2162124A1 (es)
KR (1) KR20100002304A (es)
CN (1) CN101677974A (es)
AR (1) AR068608A1 (es)
AU (1) AU2008258787A1 (es)
BR (1) BRPI0812105A2 (es)
CA (1) CA2682326A1 (es)
IL (1) IL202506A0 (es)
MX (1) MX2009012761A (es)
TW (1) TW200916091A (es)
WO (1) WO2008148564A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
CN102409095B (zh) * 2011-11-17 2013-08-07 哈尔滨医科大学 先天性眼球震颤基因检测试剂盒
TW201412325A (zh) * 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
AU2005265031A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet

Also Published As

Publication number Publication date
AU2008258787A1 (en) 2008-12-11
US20100234358A1 (en) 2010-09-16
WO2008148564A1 (en) 2008-12-11
CN101677974A (zh) 2010-03-24
TW200916091A (en) 2009-04-16
CA2682326A1 (en) 2008-12-11
KR20100002304A (ko) 2010-01-06
AR068608A1 (es) 2009-11-25
BRPI0812105A2 (pt) 2014-11-25
EP2162124A1 (en) 2010-03-17
IL202506A0 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IN2012DN01233A (es)
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
UA105229C2 (uk) Фармацевтичний склад
IN2012DN02735A (es)
IN2012DN02702A (es)
IN2012DN00754A (es)
TN2012000369A1 (en) 5-alkynyl-pyrimidines
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
TW200942524A (en) Novel aminomethyl benzene derivatives
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MX2010002734A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201300990A1 (ru) Парентеральное введение тапентадола
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
TN2012000105A1 (en) Spirolactam derivatives and uses of same
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
MX2010009837A (es) Tiazolil-dihidro-indazoles.
WO2010012745A3 (en) Benzimidazoles
UA103996C2 (en) Ivabradine hydrobromide
TN2011000531A1 (en) 5- alkynyl - pyridines
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal